Diovan Hct
Product Images NDC 68258-6053

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Diovan Hct (NDC 68258-6053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 68258-6053-xx (Ndc 68258 6053 Xx Novartis)

Diovan HCT 160 mg/25 mg tablets label showing prescription drug information. The label displays active ingredients valsartan 160 mg and hydrochlorothiazide 25 mg per tablet. It includes directions to take one tablet orally once daily as directed by a doctor, with warnings about pregnancy risks and possible drowsiness or dizziness. Labels indicate the product is for RX only and packaged exclusively by Dispensing Solutions, Inc.*

FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Diovan Hct 01)

A line graph showing percent systolic blood pressure reduction (SBP-140 mmHg) on the vertical axis versus baseline systolic blood pressure (SBP in mmHg) on the horizontal axis. The graph compares the effects of Diovan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, with distinct symbols representing each treatment.*

FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Diovan Hct 02)

A line graph comparing the effects of Diovan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo on baseline diastolic blood pressure (DBP) in mmHg. The x-axis shows baseline DBP values from 90 to 110 mmHg, and the y-axis shows change in DBP from 0 to 100 mmHg, with data points indicated by different symbols for each treatment group.*

FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Diovan Hct 03)

A line graph depicting the percentage of patients achieving systolic blood pressure (SBP) below 140 mmHg in relation to baseline SBP values. Four treatment groups are shown: Diovan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. The graph illustrates comparative efficacy across the baseline SBP range of about 140 to 180 mmHg.*

FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Diovan Hct 04)

A line graph showing percentage reduction in Diastolic Blood Pressure (DBP) from baseline over a range of baseline DBP values (90 to 110 mmHg). The graph compares responses for Diovan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and a placebo group.*

FDA Label Image

Valsartan Structural Formula (Diovan Hct 05)

Chemical structure diagram of the active ingredient in Diovan HCT.*

FDA Label Image

Hydrochlorothiazide Structural Formula (Diovan Hct 06)

Chemical structure diagram of the active ingredient in Diovan HCT, showing a chlorinated benzene ring with attached sulfonamide and other functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.